Breast Cancer

Imagine a woman with a weight problem who, two weeks after chemotherapy, goes to her doctor with a urinary tract infection and a rash on her upper chest.

A breast cancer and melanoma survivor shares her perspective on living with "wait and watch."

A recent study enrolled 1,589 black women and 1,256 white women who underwent screening mammography at the University of Pennsylvania from 2010 to 2011.

It's easy to feel alone dealing with cancer. Being a part of a social media community that "gets it" can be invaluable to healing.

Everyone's chemotherapy experience is unique.

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Cancer Survivors Beauty and Support Day is an annual event on the first Tuesday in June where those in the beauty industry volunteer services to cancer patients and survivors.

The PALOMA-3 trial examining an Ibrance (palbociclib) regimen in HR-positive/HER2-negative breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management and healthy eating.

Breast cancer patients with diabetes were significantly more likely to be diagnosed with advanced-stage breast cancer than those without diabetes.

I cherish the moment I found support and realized I wasn't alone. Giving back in gratitude for that support was the next step in healing from my cancer.

Many women who are diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer. However, a large amount of those concerns are not being addressed, according to a new study.

After treatment for stage 4 colorectal cancer, a country singer is using his talents to express his gratitude and help others.

It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.

Diet is precisely where we have the opportunity to provide our bodies with cellular mediators of inflammation.

Hyman B. Muss, professor of oncology at the University of North Carolina and director of geriatric oncology at the Lineberger Comprehensive Cancer Center, discusses how patients with breast cancer should press their physicians to help them make the best medical decisions.

Jean M. Weigert, head of breast imaging for the Hospital of Central Connecticut, discusses results of a study examining supplemental ultrasound screening in women with dense breast tissue.

Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.

Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.

Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.

Breast cancer specialist Mark Pegram discusses recent breast cancer studies and what's to come for patients with HER2-positive breast cancer.

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.

Surgical oncologist Kelly K. Hunt, of MD Anderson Cancer Center, discusses how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and the role of sentinel lymph node dissection in the neoadjuvant setting.

First-line treatment with Tykerb and a taxane failed to improve progression-free survival versus Herceptin plus a taxane in patients with HER2-positive metastatic breast cancer.

Inflammatory breast cancer survivor, Terry Arnold, shares her story of diagnosis and survivorship.